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The purpose of this study was to formulate hemin as a powder for 
inhalation and to show proof of concept of heme oxygenase 1 (HO-1) 
expression in the lungs of mice by inhalation of hemin. Hemin was 
spray dried from a neutralized sodium hydroxide solution. The particle 
size distribution of the powder was between 1-5 μm. Dispersion from 
the Twincer dry powder inhaler showed a fine particle fraction (<5 
μm) of 36%. A specially designed aerosol box based on the Twincer®-
inhaler was used for a proof of concept study of HO-1 induction by 
inhalation of hemin in mice. The aerosol in the exposure chamber of 
the aerosol box remained aerosolized up to 5 minutes. A rhodamin B 
containing aerosol was used to show that the aerosol box gave 
deposition over the entire lung indicating the suitability of the model. 
Additionally, inhalation of hemin showed a dose dependent increase in 
HO-1 protein expression in the lungs. In conclusion, hemin was 
successfully formulated as a powder for inhalation and the inhalation 
model allowed controlled HO-1 expression in the lungs of mice. Future 
studies investigating the utility of inhaled hemin in treating disease 
states are warranted. 
 




The heme oxygenase (HO) metabolic pathway has recently received an 
explosion of research interest due to its potent physiological and 
cytoprotective properties, e.g. (1-3). The inducible (HO-1) and the 
constitutively expressed (HO-2 and HO-3) forms of HO catalyze the 
oxidation of heme to biliverdin, carbon monoxide and iron (4). 
Subsequently, biliverdin is rapidly converted to bilirubin which is a potent 
endogenous antioxidant (5). All three downstream products 
(biliverdin/bilirubin, CO and Fe/ferritin) participate in the cellular 
defense. HO-1 has an integral role in the response to oxidative stress and 
inflammation and is induced by numerous oxidative and inflammatory 
stimuli (6). 
Recently, it was shown that HO-1 expression in lung tissue and 
macrophages obtained by bronchoalveolar lavage of patients with chronic 
obstructive pulmonary disease (COPD) is decreased compared with 
healthy controls (7, 8). COPD is a respiratory disease characterized by a 
chronic inflammatory response in the lungs, which is primarily caused by 
the toxic effects of smoking. It is tempting to hypothesize that in COPD 
patients an imbalance between systemic reactive oxygen species and 
relative antioxidant systems exists, which is possibly caused by 
insufficient upregulation of HO-1 (9). One of the substances that induces 
HO-1 is hemin (ferriprotoporphyrin IX), the oxidized form of heme (10, 
11). Induction of the heme oxygenase pathway by inhalation of natural 
substrates, such as hemin, could therefore be of great benefit in diseases 
like COPD (12, 13). So far, inhalation of hemin in humans has been 
performed only once as a control to show that the HO-1 pathway is 
involved in asthma (13). In that study, nebulization of 2 ml of 10–4 M 
hemin resulted in increased levels of exhaled CO, indicating that the HO-
1 pathway can be induced by inhalation of hemin. However, no direct 
evidence of HO-1 induction was given. 
In the clinical setting, nebulization is characterized by a low deposition 
efficiency (typically 2-27%), and needs electricity or pressurized air for 
the aerosol to be created. In contrast, dry powder inhalation is 
characterized by higher deposition efficiency (up to 60%) and the patient 
delivers the driving force for the aerosol to be created (14-17). Moreover, 
nebulization is accompanied by patient immobility, whereas dry powder 
inhalers are easy to carry and use. Furthermore, dry powder inhalation is 




The aim of this study was to formulate hemin as a powder for inhalation 
and to show a proof of concept for induction of heme oxygenase 1 
expression in the lungs of mice by inhalation of hemin. To obtain the 
proof of concept we administered hemin as a powder for inhalation to 
mice by using a specially designed aerosol box, which is based on the 
Twincer® dry powder inhaler (18).  
 
MATERIALS AND METHODS 
Materials 
Hemin (51280) and rhodamin B (83689) were purchased from Sigma-
Aldrich Chemie B.V. (Zwijndrecht, The Netherlands). Inulin, with a 
degree of polymerization of 23, was a generous gift of Sensus (Breda, The 
Netherlands). Sodium hydroxide (NaOH), hydrochloric acid (HCl) and 
ammonia (NH4) were of analytical grade and purchased from commercial 
suppliers. Demineralized water was used throughout the experiments. 
 
Methods 
Quantitative determination of hemin 
Sample concentrations for determination of solubility and drug load were 
spectrophotometrically analyzed in phosphate buffered saline (PBS) with 




In order to measure the maximum solubility in different alkaline 
solutions, 7 solutions with a pH between 11.0 and 14.0 were prepared in 
steps of 0.5 pH units. To these solutions excess hemin was added under 
constant stirring. After 30 minutes, the solutions were centrifuged at 
10,000 rpm for 10 minutes. The supernatant was pipetted and diluted 
with a phosphate buffered solution and measured spectrophotometrically.  
 
Powder production by spray drying 
Due to an excess of sodium hydroxide in the solution to increase 
dissolution of hemin, the pH of that solution remains high. If such a 
solution is spray dried, the resultant powder causes an alkaline pH shift 
upon reconstitution. To avoid alkaline pH changes upon reconstitution of 
the spray dried powder, the pH needs adjustments during or before spray 
drying. Two methods were used for pH adjustment. In the first method a 
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sodium hydroxide solution (0.7% w/v) with pH 13.5 was immediately 
before spray drying adjusted to pH 7.6 with hydrochloric acid. The second 
method consisted of spray drying an ammonia solution (1.2% w/v) with a 
pH of 13.5. During spray drying, ammonia evaporates and is not present in 
the dried powder any longer.  
Four powders were spray dried. The first powder was prepared by 
dissolving hemin in a sodium hydroxide solution (0.7% w/v) at a pH of 13.5 
to obtain a total concentration of 4.5% w/v. After pH adjustment the 
solution was filtered through a 1.2 µm filter. Hemin was not removed by 
filtration from the solution. After spray drying, this powder thus 
contained sodium chloride and hemin. The hemin drug load was 
determined to be 63% w/w. 
The second powder was produced by dissolving hemin in an ammonia 
solution (1.2% w/v) with a pH of 13.5. After spray drying, this powder 
thus only contained pure hemin. This powder was used as a control in the 
dissolution experiments. 
Finally, spray dried controls containing rhodamin B or inulin were 
prepared by dissolving the respective controls in a sodium hydroxide 
solution followed by pH adjustment before spray drying. Rhodamin B 
served as a control for the in vivo deposition characteristics and thus the 
suitability of the aerosol box; inulin served as a control for the local 
effect of powder inhalation with sodium chloride.  
Spray drying was performed with a Büchi 190 Mini Spray Dryer (Büchi, 
Flawil, Switzerland) equipped with a two-fluid nozzle (0.5 mm). The 
solutions were sprayed at a fluid flow rate of 3.2 ml/min and an 
atomizing air flow rate of 800 l/h. The settings of the aspirator (14) and 
heater (14) resulted in temperatures at the inlet and outlet of 180 °C and 
120 °C, respectively. 




Dissolution experiments were carried out using an USP dissolution 
apparatus I (Rowa Techniek B.V., Leiderdorp, The Netherlands) at 37 ºC 
and 100 rpm in 1000 mL phosphate buffered solution with 10 mg hemin, 
corrected for drug load. Samples from the dissolution vessel were 





Laser diffraction, scanning electron microscopy and cascade impactor 
analysis 
Particle size distributions of the spray dried samples were measured with 
a Helos Compact model KA laser diffraction apparatus (100 mm lens, 
Fraunhofer theory) equipped with a RODOS dispersing system (Sympatec 
GmbH, Clausthal-Zellerfeld, Germany) operated at a dispersion pressure 
of 5 bar. All measurements were performed in triplicate. The particle size 
distribution in the exposure chamber was measured by placing the 
complete aerosol box in the laser beam. To avoid scattering by the 
Perspex walls, the light was directed through two opposing openings. 
Scanning electron micrographs (SEM) were recorded with a JEOL JSM 
6301-F Microscope (JEOL, Japan). The powder was dispersed on top of 
double-sided sticky carbon tape on metal disks and coated with 150 nm of 
gold/palladium in a Balzers 120B sputtering device (Balzers UNION, 
Liechtenstein). 
The aerodynamic particle size distribution was measured with cascade 
impactor analysis using a multi-stage liquid impinger (Erweka, 
Heusenstamm, Germany) with a Twincer®-inhaler (18) attached to the 
induction port. A solenoid valve was used in combination with a timer to 
control the flow (corresponding with 4 kPa pressure difference) through 
the inhaler and the cascade impactor for the duration of 3 seconds. The 
stages of the cascade impactor were filled with 20 mL phosphate buffered 
saline (PBS). A total amount of ~100 mg was delivered in 10 separate 
doses. The concentration of the drug on the different stages was 
measured by UV absorbance at 385 nm; deposition was subsequently 
calculated as the percentage of the metered dose. The fine particle 
fraction (< 5 μm at the flow rate corresponding with 4 kPa across the 
Twincer, FPF) was calculated by interpolation of the cumulative mass plot 
versus effective cut-off diameter. The FPF is expressed as a percentage of 
the metered dose. All cascade impactor experiments were carried out in 
triplicate. 
 
Aerosol box for passive pulmonary delivery of powders for inhalation 
As a proof of concept of HO-1 induction by inhalation of hemin a new 
device was developed to allow passive, pulmonary dry powder delivery to 
small laboratory animals. The device, hereafter called aerosol box (figure 
1), is actually an accessory for the Twincer®, an effective dry powder 
inhaler which delivers high dosed formulations in highly constant particle 
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size distributions (fine particle fraction of 40-50%) independent of the 
pressure drop between 1 and 4 kPa (18). The efficient aerosol generation 
at low pressure drops makes the Twincer® most suitable for the aerosol 
box where the operator manually generates the air flow that disperses 
the powder. The device consists of the Twincer®, a cylinder with piston to 
provide a pressure drop across the inhaler and transfer of the aerosol to 
last part of the device, the exposure chamber in which a fan is built. Mice 
are attached to the exposure chamber. In total, up to twelve mice can be 
attached to the exposure chamber. 
About 15 mg of powder, equivalent to 9.45 mg active ingredient (hemin, 
inulin or rhodamin B) and 5.55 mg sodium chloride, was dispersed in the 
aerosol box. In this study, one dose is defined as 5 minutes exposure to an 
aerosol that has been generated from 15 mg of drug formulation. 
 
Animals 
Female A/J mice (aged 8-10 weeks) were obtained from Harlan (Zeist, 
the Netherlands) and were held at the Central Animal Facility of the 
Groningen University. The experiments were approved by the Committee 
on Animal Experimentation of the University Medical Center Groningen 
and were performed under strict governmental law, adhering to the 
Principles of Laboratory Animal Care. 
 
Experimental setup 
The mice used in this study were divided into 6 groups. Group 1 consisted 
of one mouse that was not exposed to any aerosol and served as a 
control. Groups 2, 3, 4 (n=2 for each group) were exposed to 2, 4 and 6 
doses of spray dried hemin, respectively. Group 5 (n=2) was exposed to 6 
doses of spray dried inulin and served as control for sodium chloride that 
was present in the spray dried powders. Inulin, a naturally occurring 
oligosaccharide was chosen because oligosaccharides contribute 
marginally to the osmotic pressure due to their high molecular weight. 
Group 6 (n=2) was exposed to 6 doses of spray dried rhodamin. Group 6 
was used to investigate the deposition of dispersed powder in the lungs of 
mice. Deposition of rhodamin was visualized in 4 µm sections of frozen 







































Figure 1. (Top) The aerosol box, a utility for the Twincer® (A). By pulling the 
piston in the cylinder (B) an aerosol is created and can be transferred to the 
exposure chamber (C) to which 12 small laboratory animals can be fitted. A fan 
(D) creates a laminar airflow in the exposure chamber to minimize sedimentation 
effects. (Middle) Detail of the Twincer® attached to the aerosol box. (Bottom) 
Detail of mouse attached to exposure chamber. 




Protein samples were made from whole lung tissue using a sonicator 
(Bandelin sonopuls HD2070, Berlin, Germany). The proteins were 
separated on molecular weight using Sodium Dodecyl Sulphate-
Polyacrylamide Gel Electrophoresis (SDS-PAGE) and blotted on a 
nitrocellulose membrane. The membrane was blocked overnight in 5% low 
fat milk and the proteins were detected with anti-heme oxygenase-1 
(Stressgen, Victoria, Canada) followed by a peroxidase labeled goat-anti-
rabbit antibody (DakoCytomation, Heverlee, Belgium). As a protein 
loading control the membrane was stripped using an 25mM Glycine-HCl 
buffer containing 1% SDS (pH:2) and stained for β-actin (Abcam loading 
control, Cambridge, UK) followed by a peroxidase labeled goat-anti-rabbit 
antibody (Dako). The bands of interest were visualized using enhanced 
chemiluminescence. 
Band-sizes of each group were quantified using Matlab 6.5.1 (The 
MathWorks Inc, Natick, USA) and the Dipimage toolbox (Quantitative 
Imaging Group, Faculty of Applies Sciences, Delft University of 
Technology, the Netherlands) (19, 20). In short, the grey-scale images 
were made binary with the Isodata threshold algorithm which calculates 
the best threshold value out of the grey value histogram of the image 
(21). Data are given as the ratio between the number of pixels of the HO-




HO-1 protein expression was demonstrated in 3 µm sections of paraffin 
embedded lung tissue with antibodies against HO-1 (Stressgen 896, San 
Diego, CA, United States). Presence of leukocytes was demonstrated in 4 




Formulation. A series of experiments was carried out to measure the 
solubility of hemin at different pH levels. Hemin is practically insoluble in 
water (at pH ~7) and organic solvents (22). However, under alkaline 
conditions hemin is soluble. In alkaline solutions, hemin (FePP-Cl) reacts 




intermediate in a polymerization reaction which results in a oxy-bridged 
dimer and probably other polymers (22). 
 
FePP-Cl + OH- → FePP-OH + Cl- 
2FePP-OH → (FePP)2O + H2O 
 
The solubility of hemin (figure 2; solid line, primary y-axis) reached a 
maximum at pH 13.5. At pH>13.5 a large variation in solubility was 
observed which indicates the occurrence of degradation reactions, such 
















Figure 2. Solubility of hemin (solid line, primary y-axis) as a function of pH and 
calculated content of hemin in spray dried powder (dotted line, secondary y-axis) 
as a function of pH. The calculated concentration of NaOH versus pH is 
represented by the dashed line (primary y-axis).(n=3) 
 
Since the pH of the sodium hydroxide solution determines the amount of 
hemin that can be dissolved, the sodium hydroxide concentration is the 
main parameter that determines the efficiency of the spray drying 
process. The higher the sodium hydroxide concentration, the higher the 
hemin concentration in the solution. On the other hand, it should be 
realized that an increase in the sodium hydroxide concentration requires 
increased amounts of hydrochloric acid for neutralization. This effect will 
lead to a shift towards higher sodium chloride fractions in the powder, 
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which of course reduces process efficiency in terms of drug load. Finding 
the most efficient process condition is a matter of balancing between the 
solubility of hemin, which is positively affected by the sodium hydroxide 
concentration, and the hemin drug load in the powder, which is 
negatively affected by the sodium hydroxide concentration. These effects 
are shown in figure 2 (dotted line, secondary y-axis). 
 
With increasing pH the drug load of hemin in the spray dried product 
initially rose up to a maximum of 90% at a pH of 11.8. At this pH the total 
concentration of hemin and NaOH was only 2.5 mg/ml. Spray drying of a 
solution with such a low concentration does not result in a high yield. 
Therefore the pH was increased to 13.5, which resulted in a solution with 
a total concentration of 45 mg/ml and a drug load of 63% after spray 
drying as was confirmed by chemical analysis. The spray dried hemin 
powder consisted of highly irregular particles (figure 3), which were in a 


























Table 1. particle size obtained from RODOS dispersion (5 bar) at 10, 50 and 90% 
cumulative undersize of the spray dried powders. All powders were spray dried 
from a sodium chloride solution, except pure spray dried hemin, which was spray 











Spray dried hemin 1.01 2.14 3.67 1.25 
Spray dried hemin from ammonia 0.95 2.06 3.50 1.24 
Spray dried inulin 0.92 2.29 4.66 1.64 
Spray dried rhodamin B 0.87 2.02 3.42 1.26 
* Span = (x90-x10)/x50 
 
Spray dried hemin from a neutralized sodium chloride solution displayed a 
faster dissolution profile compared to spray dried hemin from NH3 as 
shown in figure 4. After 2 minutes 50% of spray dried hemin was 
dissolved, compared to 20 minutes for spray dried hemin from NH3, while 


















Figure 4. Dissolution rate of spray dried hemin in the presence of NaCl (z) and 
pure spray dried hemin from ammonia ({). (n=3) 
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Complete dissolution of the powder spray dried from the NH3 solution 
took 110 minutes. The powder with the fastest dissolution rate was used 
to perform further experiments (aerosol behavior and proof of concept).  
In table 1 the particle size distributions of the spray dried powders are 
shown. The particle size distributions are comparable, only spray dried 
inulin had a somewhat wider size distribution.  
Cascade impactor analysis (figure 5) showed a delivered dose from the 
Twincer at 4 kPa of approximately 77% with a fine particle fraction (<5 



















Figure 5. Cascade impactor analysis of spray dried hemin with NaCl after 
dispersion by the Twincer® at 4 kPa. Fine particle fraction (FPF) represents 
particles <6.8 µm. Error bars represent highest and lowest value. 
 
Validation of aerosol box.  
After dispersion in the aerosol box (figure 6B), most particles (<90%) were 
between 1 and 5 μm. In the aerosol box the size distribution moved 
towards finer particles in time, indicating sedimentation. Larger 
agglomerates (5-10 μm) sediment fast and such agglomerates are no 
longer present after 1 minute. The change in particle size distribution will 




since the volume fraction of such agglomerates in the aerosol is small. 
Sedimentation was confirmed by a decline in the optical concentration 
(i.e. amount of laser light that is blocked by the aerosol). After 5 minutes 
the optical concentration was 0.0%, whereas the starting concentration 
was 1.54% on average. The amount of aerosol in the exposure chamber 
after 5 minutes was therefore negligible due to sedimentation. Therefore, 
we exposed the mice for 5 minutes per dose to the aerosol because a 


























Figure 6. (A) Geometrical particle size distributions of spray dried hemin as 
measured by RODOS dispersion at 5 bar and (B) in the exposure chamber of the 
aerosol box immediately (────), 1 minute (········), 2 minutes (─  ─  ─), 3 
minutes (─ ·· ─), 4 minutes (──  ──) and 5 minutes (─ · ─ ·) after dispersion by 
the Twincer®. (Fig.4A: n=3; Fig.4B n=4) 
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To obtain an indication of the amount of drug that a mouse actually 
inhales, an in vitro measurement was performed by withdrawing 20 
ml/min of air during 5 minutes from the exposure chamber. It was shown 
that this volume contained about 0.02% of each dose, an amount that 
consequently can be assumed as the administered dose. The assumption 
of 20 ml/min was on the low side, since respiratory minute volumes of 
mice of 45 – 50 ml/min have been described (23, 24). 
In vivo deposition of inhaled powder in the lungs from the aerosol box was 
demonstrated by exposing mice to rhodamin B. Rhodamin B had a similar 
particle size distribution as spray dried hemin (Table 1). By using 
fluorescent microscopy, rhodamin deposition on the epithelial lining of 
the airways was demonstrated (figure 7). Rhodamin deposition was 


















Figure 7. Example of rhodamin fluorescence in lung tissue. The fluorescent signal 
(red) of rhodamine in lung tissue is shown to be present in the epithelial lining of 
the airways. Magnification: 20x 
 
Proof of concept 
Different doses of spray dried hemin were administered to achieve HO-1 
induction in lung tissue. Figure 8 shows a clear relationship between the 




homogenate. Furthermore, inhalation of inert powder (spray dried inulin) 
containing sodium chloride did not result in increased expression of HO-1.  
HO-1 protein expression was found to be particularly increased in alveolar 
macrophages (figure 9). The airway epithelium stains faintly and shows no 
differences after hemin inhalation. The HO-1 expression as shown with 
HO-1-staining in the spray dried inulin exposed mice was comparable to 




















Figure 8. (A) HO-1 protein expression. Protein bands for HO-1 (top) and β-actin 
(loading control, bottom) detected by Western blot analysis are shown; each 
band represents 1 mouse. From left to right: one control mouse that was not 
exposed to aerosol, 2 mice that were exposed to 2, 4 or 6 doses (2x, 4x and 6x) 
of spray dried hemin during 10, 20 or 30 minutes, respectively, and finally 2 mice 
that were exposed to 6 doses spray dried inulin (6x inu) during 30 minutes. (B) 
Ratio of the HO-1 and -actin band size as obtained with Western blot for the 





























Figure 9. A representative picture of the HO-1 expression (dark red) in lung 
tissue of the control and after inhalation of 2, 4 and 6 doses of spray dried hemin 
is shown (25x magnification). Particularly, alveolar macrophages (indicated with 
an arrow) show an increased HO-1 expression after hemin inhalation. 
Magnification: 25x 
 
The inflammatory side effects of spray dried hemin inhalation were 
studied by histological staining of leukocytes in lung tissue. Visual 
observation showed increased numbers of leukocytes surrounding the 
airways after inhalation of 4 and 6 doses of spray dried hemin, while in 
the control mouse and after inhalation of 2 doses of spray dried hemin 






























Figure 10. Leukocytes expressed in lung tissue. A representative picture of the 
leukocyte expression (CD45 positive cells) in lung tissue of the control and after 
inhalation of 2, 4 and 6 doses of spray dried hemin is shown. Arrows in top 
pictures indicate airways; arrows in bottom pictures indicate areas with 
increased numbers of leukocytes surrounding the airways. Magnification: 50x 
 
DISCUSSION 
Hemin, as shown in this study, can be formulated as a powder for 
inhalation by spray drying. Furthermore, spray dried hemin resulted in 
dose-dependent HO-1 induction after nose-only exposure of mice to the 
aerosol, showing that dry powder inhalation of hemin is possible and 
effective in inducing the HO-1 metabolic pathway.  
Spray drying of hemin was performed from two solutions that had initial 
high pH values. An advantage of spray drying an ammonia solution that 
contains hemin is that ammonia evaporates during spray drying, resulting 
in pure hemin powder. In contrast, spray drying of the neutralized sodium 
hydroxide solution results in a powder that contains 37% w/w sodium 
In vivo induction of heme oxygenase I 
 
207 
chloride and 63% w/w hemin. However, the latter solution results in a 
powder that dissolves much more rapidly than the pure spray dried 
powder. This is attributed to the presence of sodium chloride in the spray 
dried powder which improves wetting and increases the surface over 
which dissolution occurs. The technique may be beneficial for other 
poorly soluble compounds too, especially for those compounds that have 
a pH-dependent solubility. 
Spray drying has become one of the standard techniques for the 
preparation of inhalation powders (25, 26). One of the advantages of 
spray drying over conventional techniques such as milling is the improved 
control over the particle size. From both the sodium hydroxide and 
ammonia solution the obtained powders were in the appropriate size 
range for inhalation, as measured with laser diffraction and cascade 
impactor analysis. 
Clearly, the sodium chloride in the formulation did not increase HO-1 
expression as was shown by the similarity in band size of HO-1 expression 
of the inulin control, after 6 doses, and the control that did not receive 
any aerosol.  
The suitability of the Twincer-based aerosol box for pulmonary 
administration in freely breathing mice was demonstrated in this study. 
The in vitro laser diffraction measurements showed that an aerosol 
consisting of particles suitable for inhalation is present in the aerosol box 
for at least 5 minutes. Moreover, the in vivo study with rhodamin B 
showed that the aerosol reached all parts of the lung. It should however 
be realized that the individual mouse receives only a small fraction, 
about 0.02%, of the total dose in the Twincer. The major limitation in this 
setup is the relative small volume that is inhaled by mice. 
One study exists where inhalation of hemin in human subjects has been 
investigated (13). However, the dose in our study is much higher than the 
dose used in the human study. The nebulized dose in the human study 
was 2 ml of 10-4 M hemin, which is equivalent to 1.6 μg/kg for a person of 
80 kg. The lowest dose in our study is estimated to be 171 μg/kg, which 
corresponds to at least 100 times the dose used by Horvath et al. (13). 
Since there was no information available on the dose-effect relationship 
of hemin we exposed mice to different doses. The dose escalation in our 
study was thus 171, 342 and 523 μg/kg. The relatively high doses that the 
mice inhaled led to concerns about the toxicity of hemin since it has been 




doses which is due to excess iron (27). Ambiguous effects have been 
ascribed to hemin (28). In moderate amounts and bound to proteins it is 
an essential element in various biological processes (10, 29). Large 
amounts of hemin can be toxic by mediating oxidative stress and 
inflammation, which is mainly due to release of iron (27). 
The higher doses indeed led to infiltration of leukocytes into the airways. 
This inflammatory cell recruitment could be the result of increased 
production of inflammatory mediators by epithelial cells in response to 
toxic effects of the increasing dose of spray dried hemin. This possibility 
is in agreement with other in vitro and in vivo studies showing increased 
adhesion molecule expression and tissue infiltration of leukocytes after 
hemin administration to vascular cells (30, 31). On the other hand, we 
found that 171 μg/kg hemin did not result in increased numbers of 
inflammatory cells. However, inhalation of this dose of spray dried hemin 
was sufficient for a clear increase in HO-1 expression in lung tissue, 
indicating that this was a safe and effective dose of spray dried hemin. 
To conclude, we presented a novel preparation of a hemin formulation by 
spray drying and showed proof of concept of the hemin formulation and a 
new pulmonary administration technique. The substance, hemin, induced 
the HO-1 expression in a dose dependent manner. Future studies 
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